Keith Robison has a post on his Omics! Omics! blog about Roche's seemingly unquenchable thirst for acquisition targets. Robison recaps the recent acquisitions of 454 and NimbleGen, as well as the company's currently-in-play bid for Ventana, and ponders how these units could function together as well as what kind of technology might be next on Roche's shopping list.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Five researchers are to share this year's Albany Medical Center Prize for their work on the CRISPR/Cas9 gene-editing tool, the AP reports.

Stat News reports on how white supremacists cope with surprising genetic ancestry testing results.

In Genome Research this week: sex-biased gene expression evolution in malaria mosquitos, method to find ancient selective sweeps, and more.

Iceland has nearly eliminated Down syndrome from its population, CBS News reports.